Immunic, inc. reports first quarter 2024 financial results and provides corporate update
– substantially bolstered balance sheet through a three-tranche private placement totaling up to $240 million, extending cash runway into the third quarter of 2025, based on initial $80 million tranche – – received fourth u.s. patent directed to use of vidofludimus calcium in multiple sclerosis; multilayered intellectual property strategy provides protection into 2041 in the united states – – twin phase 3 ensure trials in relapsing multiple sclerosis and phase 2 calliper trial in progressive multiple sclerosis remain underway – – webcast to be held today, may 8, 2024, at 8:00 am et – new york , may 8, 2024 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended march 31, 2024, and provided a corporate update. "during the first quarter and subsequent period, we have continued to advance both the phase 2 calliper trial in patients with progressive multiple sclerosis (pms) and the twin phase 3 ensure trials in relapsing multiple sclerosis (rms), for our potentially groundbreaking, orally available lead asset, nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838)," stated daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission